Survivorship, late effects and secondary malignancy

01Role and principlesWho benefits and the main preventive aims.

A cancer survivor is anyone living after a cancer diagnosis, whether cured, in remission, on long-term treatment or living with controlled disease. Needs do not start only when oncology follow-up ends. Acute toxicity can persist, delayed toxicity may first appear decades later and recurrence risk changes over time. Survivorship care therefore combines tumour-specific surveillance with a structured account of what treatment could have damaged. The plan should be proportionate: excessive tests can produce radiation, false positives and anxiety, while generic discharge without an exposure record leaves predictable late effects invisible.

The treatment summary is the clinical map. It records diagnosis, stage and pathology; operations and organs altered; systemic agents, cumulative anthracycline and alkylator exposure; radiotherapy field and dose; transplantation; major acute toxicity; inherited predisposition; and ongoing endocrine or maintenance therapy. From this, clinicians anticipate organ systems at risk. Examples include heart disease after anthracyclines or chest irradiation, pulmonary fibrosis after thoracic treatment, thyroid dysfunction after neck irradiation, pituitary deficits after cranial treatment, renal injury after platinum or nephrectomy, neuropathy after taxane or platinum, lymphoedema after nodal treatment, bone loss after endocrine deprivation and fertility or sexual consequences after pelvic or gonadal therapy.

Recurrence surveillance and secondary-cancer prevention are related but distinct. Follow the cancer-specific evidence-based schedule for examination, imaging, endoscopy or biomarkers. Do not use routine whole-body scanning because someone is anxious when guidance does not support it; instead create a rapid route for new symptoms. Secondary malignancy can arise from shared risk, an inherited syndrome or treatment-related DNA damage. Radiation increases later solid-tumour risk within or near exposed fields; alkylators and topoisomerase-II inhibitors increase therapy-related myeloid neoplasm risk. Standard population screening continues unless a specialist pathway recommends earlier or additional screening for treatment or genetic exposure.

Recovery is multidimensional. Fatigue, cognitive change, pain, neuropathy, bowel or bladder dysfunction, altered body image, menopause or androgen deficiency, sexual difficulty, fear of recurrence, financial toxicity and return-to-work barriers often overlap. A holistic needs assessment should lead to specific actions, not a checklist filed without referral. Exercise, smoking cessation, alcohol moderation, vaccination, healthy weight, blood-pressure and lipid control improve general health and may reduce treatment-amplified risk. The survivor needs to know who owns each planned test, how results will be acted on and which symptoms bypass routine follow-up.

Key points

Survivorship begins at diagnosis and includes recurrence surveillance, late-effect prevention, new-cancer risk, rehabilitation, medicine review and support for identity, work, relationships and finances.
First-line survivorship assessment uses an end-of-treatment summary: histology and stage, surgery, systemic agents and cumulative doses, radiotherapy fields and dose, transplant, complications, genetics and current medicines.
A treatment summary should generate a personalised care plan naming surveillance, late-effect tests, vaccination, health-promotion actions, red flags, contact routes and ownership between specialist and primary care.
Follow tumour-specific surveillance guidance rather than adding unproven scans or tumour markers; symptom-triggered investigation remains essential between scheduled reviews.
Anthracyclines and chest radiotherapy can cause cardiomyopathy, coronary, valve and pericardial disease years later; cardiovascular risk-factor control and exposure-based surveillance are central.
Pelvic, gonadal, cranial and neck treatment can cause infertility, sexual dysfunction, thyroid or pituitary failure and bone loss; ask directly because symptoms may be gradual or embarrassing.
Therapy-related myeloid neoplasms and radiation-field solid cancers are uncommon but important; persistent cytopenia or a new focal alarm feature needs a fresh diagnostic pathway.
Manage fatigue by looking for recurrence, anaemia, endocrine disease, sleep disorder, pain, mood and deconditioning, then use paced exercise and rehabilitation rather than a single supplement or stimulant.

02Assessment and patient selectionRisk features, eligibility and important cautions.

Cardiotoxicity phenotype

Breathlessness, oedema, chest pain, exercise intolerance or arrhythmia after anthracycline, HER2 treatment or chest radiation may emerge during therapy or years later.

Endocrine late effect

Fatigue, weight change, cold intolerance, postural symptoms, amenorrhoea, low libido or polyuria can reflect thyroid, pituitary, adrenal or gonadal injury.

Neurological and cognitive burden

Neuropathy, focal deficit, hearing loss, cognitive slowing and sleep disturbance may arise from cancer, treatment, medicines or a new neurological disease.

Lymphatic and musculoskeletal harm

Limb swelling, recurrent cellulitis, reduced shoulder movement, fracture, avascular necrosis and sarcopenia can follow nodal surgery, radiotherapy, steroids or endocrine treatment.

Possible second cancer

A new mass, bleeding, persistent cytopenia or field-specific alarm symptom years after treatment requires a new diagnostic assessment rather than an assumption of recurrence.

Psychosocial late effect

Fear, depression, traumatic stress, relationship strain, sexual difficulty and financial or employment loss can persist after physical recovery and deserve structured intervention.

Red flags requiring action

Progressive focal pain, unexplained weight loss, a new mass, bleeding or organ-specific alarm symptoms require investigation rather than attribution to survivorship anxiety.
New exertional breathlessness, orthopnoea, chest pain or palpitations after anthracycline, HER2 therapy or chest radiotherapy may represent treatment-related cardiovascular disease.
Syncope, hypotension, vomiting, hyponatraemia or hypoglycaemia after cranial, pituitary or adrenal treatment raises endocrine failure.
Persistent cytopenia, bruising or recurrent infection after cytotoxic therapy may reflect marrow failure, therapy-related myeloid neoplasm or another haematological disorder.
Severe distress, suicidal thought, substance dependence, inability to work or disabling fear of recurrence needs active assessment and support, not reassurance alone.

03Baseline assessmentMeasurements that guide the plan and track progress.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
First-line treatment-summary reconstructionFirst stepFirst line
Why
Identify the exposures that determine surveillance and late-effect risk.
Interpretation and limitations
Retrieve pathology, operation, systemic-regimen and radiotherapy records when the summary is incomplete; family recollection of a drug colour or scan is not a safe substitute for cumulative dose and field.
02
Tumour-specific recurrence surveillance
Why
Detect treatable recurrence using the evidence-supported schedule for that cancer and treatment intent.
Interpretation and limitations
Use the named examination, imaging, endoscopy or marker at its recommended interval; routine tests outside the pathway need a separate clinical indication.
03
Cardiovascular risk and cardiac assessment
Why
Find modifiable risk and subclinical or symptomatic injury after cardiotoxic exposure.
Interpretation and limitations
Check blood pressure, lipids, glucose and symptoms; ECG, echocardiography with ventricular function or strain and further imaging follow exposure-specific cardio-oncology guidance rather than annual testing for everyone.
04
Endocrine and bone evaluation
Why
Detect thyroid, pituitary, gonadal, adrenal and skeletal consequences of relevant treatment.
Interpretation and limitations
Select TSH and free T4, morning cortisol pathway, gonadal hormones, glucose and DXA from the irradiated organ, medicine and symptoms; normal TSH cannot exclude central hypothyroidism.
05
FBC and organ profile
Why
Investigate persistent fatigue, bruising, infection or renal and hepatic treatment sequelae.
Interpretation and limitations
Trend abnormalities and review medicines; unexplained persistent cytopenia requires film and haematology assessment rather than repeated observation for presumed post-chemotherapy suppression.
06
New-cancer investigation
Why
Apply the appropriate suspected-cancer pathway to a new alarm feature.
Interpretation and limitations
Previous treatment changes probability and modality choice but does not establish diagnosis; obtain site-specific imaging and tissue where required, while considering inherited susceptibility.
07
Holistic needs assessment
Why
Identify functional, emotional, sexual, social, occupational and financial needs that biomedical surveillance misses.
Interpretation and limitations
Translate each priority into an owner and intervention such as rehabilitation, psychosexual care, benefits advice or psychological therapy; a score without action is not care.

04InterventionsLifestyle, treatment and escalation options.

01At treatment completionCreate the survivorship recordFirst stepA phase of curative or intensive cancer treatment ends.

1Provide the patient and primary care team with diagnosis, stage, treatments, cumulative exposures, toxicities, ongoing medicines, genetic findings and devices or altered anatomy.
2Convert each relevant exposure into a recurrence schedule, late-effect surveillance item, vaccination or prevention action, with exact owner and next date.
3Explain red flags, urgent and routine contact routes, employment and activity advice, and arrange a treatment summary review when information is missing or circumstances change.

02Scheduled reviewSeparate recurrence, late effect and general diseaseA survivor attends planned specialist or primary-care follow-up.

1Ask about new site-specific symptoms, adherence and treatment toxicity, then examine or test according to tumour and exposure guidance.
2Review cardiovascular risk, vaccination, smoking, alcohol, weight, activity, bone, endocrine, sexual, fertility, mood, cognition and work needs rather than focusing only on recurrence.
3EscalationUpdate the plan and result ownership, de-escalating safely to supported self-management when appropriate while preserving rapid re-entry for symptoms.

03New symptomUse a fresh diagnostic pathwayA survivor develops a persistent, progressive or alarming new problem between reviews.

1Assess physiological urgency first and obtain the treatment summary to identify recurrence patterns, organ toxicity, second malignancy and common unrelated diagnoses.
2First lineOrder the first-line site-appropriate investigation and contact the treating or late-effects service when prior anatomy, radiation or systemic exposure changes interpretation.
3EscalationDo not wait for the next surveillance visit; communicate results and ensure an unresolved symptom has a documented escalation or follow-up endpoint.

04RehabilitationRestore function with targeted supportFatigue, pain, cognitive, sexual, nutritional, mobility or psychosocial burden limits life after treatment.

1Look for reversible medical contributors including recurrence, anaemia, endocrine dysfunction, infection, medicine toxicity, sleep disorder and depression.
2Offer individualised physical activity, physiotherapy, occupational, dietetic, pain, lymphoedema, psychosexual or psychological care according to the limiting mechanism.
3Set functional goals meaningful to the person, review progress and coordinate employers, benefits or social care when return to roles is constrained.

05Medicines and treatment safetyRegimens, contraindications and review points.

Reduces recurrence in hormone-sensitive disease but creates a distinct survivorship burden requiring adherence and toxicity management.

Long-term endocrine anticancer therapy

Continue the tumour-specific tamoxifen, aromatase-inhibitor or androgen-deprivation regimen for the specialist-agreed duration, documenting exact agent, dose, start date, planned stop point and any treatment break.

Monitor agent-specific thrombosis, uterine bleeding, menopausal symptoms, sexual function, bone loss, metabolic and cardiovascular effects; do not stop for toxicity without oncology discussion because alternatives may preserve benefit.

Restores protection lost through treatment and prevents severe infection in people with persistent anatomical or functional immune risk.

Vaccination after cancer treatment

Give inactivated and live vaccines according to the current UKHSA Green Book schedule for immune recovery, splenectomy, transplant and ongoing immunosuppression; timing is exposure-specific rather than a universal post-chemotherapy date.

Live vaccines may be contraindicated during significant immunosuppression and for defined periods afterward. Coordinate with transplant or haematology services and record vaccine response strategies when recommended.

Prevents fragility fracture when endocrine deprivation, premature menopause, steroids, low weight or inactivity has reduced bone strength.

Bone-protective treatment

Use calcium or vitamin D only to correct intake or deficiency and select bisphosphonate or other osteoporosis treatment from fracture risk, DXA, renal function and the current NICE pathway.

Cancer-dose antiresorptives and osteoporosis regimens are not interchangeable. Review dental and jaw risk, renal function, calcium and vitamin D and plan sequential therapy before stopping denosumab.

06Targets, monitoring and follow-upResponse, safety and longer-term review.

Maintain a shared treatment summary and care plan, updating new recurrence, second cancer, major toxicity and changes in follow-up ownership.
Complete only the evidence-based cancer surveillance at the correct interval and document who reviews each result, including tests requested from primary care.
Reassess blood pressure, lipids, glucose, smoking, activity and weight at routine intervals, intensifying prevention after cardiotoxic exposure.
Track organ-specific late effects according to dose and field, including cardiac, endocrine, bone, renal, pulmonary, auditory, neurological and reproductive function.
Ask about mood, fear of recurrence, cognition, fatigue, sexual function, work and finances repeatedly because needs emerge after acute treatment ends.
Review long-term medicines for adherence, toxicity, interactions and intended stop point, ensuring contraception and pregnancy advice remains current.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Exposure predicts surveillance

Cancer name alone cannot define late-effect follow-up; cumulative medicine dose, radiation field, surgery and transplant history are the essential variables.

More scans are not safer

Unproven surveillance can add radiation, incidental findings and false reassurance while symptom-triggered investigation remains necessary.

Second cancer is a new diagnosis

A later lesion may be recurrence, inherited-risk cancer, treatment-related malignancy or unrelated disease and usually still requires tissue classification.

Fatigue has multiple mechanisms

Deconditioning, sleep, mood, anaemia, endocrine injury, pain and ongoing therapy often coexist, so a single normal scan does not complete assessment.

Ownership prevents silent harm

A beautifully detailed surveillance schedule fails when neither oncology nor primary care knows who orders, reviews and acts on the test.

08Common pitfallsFrequent interpretation and management errors.

01
Discharging a survivor without treatment doses, radiation fields, planned surveillance or a rapid re-entry route.
02
Ordering routine tumour markers or whole-body imaging outside evidence-based surveillance because the patient is anxious.
03
Attributing every new symptom to recurrence and overlooking common treatable disease or treatment toxicity.
04
Reassuring from regular menstruation alone that fertility is preserved after gonadotoxic therapy.
05
Ignoring cardiovascular prevention because ventricular function was normal at treatment completion.
06
Recording a holistic needs assessment without assigning any intervention or reviewer.
07
Allowing a long-term endocrine medicine to continue indefinitely without a documented duration and toxicity review.